×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Loan Against Mutual Fund
Apply Now
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Vouchers
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Budget 2026
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
PF
Forum
Videos
you are here:
Home
News
Trastuzumab
Trastuzumab
Glenmark Pharma slashes price of breast cancer drug Trastuzumab
Ideas For Profit | Cadila: COVID opportunity, complex pharma pipeline offer strong risk reward
Biocon pins hopes on emerging markets to deliver in FY19
USFDA boost for Biocon: Analyst view on stock and sector
Mylan deal removes uncertainty over launch of Trastuzumab biosimilar: Biocon Chief
You cannot hang on to breast cancer drug: HC to Roche
Biocon well-poised to be a frontrunner in biosimilars: MD
Biocon at new high as USFDA accepts application for cancer drug
I don't see Trump's views affecting Indian drug cos: Biocon CMD
USFDA to review Biocon-Mylan's biosimilar drug for breast cancer
Biocon's breast cancer drug clinical data published in JAMA
Speciality offers better returns, says Biocon Chief
Demonetisation has impacted Indian sales, not exports: Biocon
Trastuzumab marketing approval may come in 12-18 months: Biocon
Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting
US, Europe filings to drive Biocon growth: Kiran Mazumdar-Shaw
Biocon up 7% on Morgan Stanley upgrade, 2016 likely to be strong
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio